Clinical Scorecard: The link between MGMT expression and outcomes in H3 G34-mutant diffuse hemispheric glioma persists after accounting for pre-analytic and technical factors

At a Glance

Key Highlights

• RNA-seq data from 110 tumors were centrally sequenced; four older-platform specimens identified as extreme outliers were excluded from both analyses.
• Normalization and batch correction removed release-year clustering and reduced correlations between MGMT and unrelated genes in raw counts.
• In the 25-patient outcome cohort, adjusted MGMT expression remained associated with progression-free survival and overall survival after accounting for four pre-analytic and technical variables.
• Associations between MGMT expression and methylation at three gene-body/intronic CpGs persisted after adjustment; promoter CpGs showed negative correlations with expression.
• The authors state that MGMT expression requires validation in larger, prospective cohorts before guiding therapy.

Guideline-Based Recommendations

Diagnosis

• The article reports research analyses and does not provide diagnostic criteria for DHG.

Management

• The authors state that MGMT expression requires validation in larger, prospective cohorts before guiding therapy.

Monitoring & Follow-up

• For retrospective RNA-seq cohort analyses, document pre-analytic variables and assess whether adjustment for them changes marker–outcome associations.

Risks

• Retrospective, multi-institutional cohorts may have batch effects related to sequencing, preservation, collection period, or tumor content.
• Low-complexity libraries may remain outliers after batch correction and cannot be rescued through correction, according to the authors.
• Correlation between MGMT expression and methylation does not demonstrate that gene-body methylation regulates MGMT.

Patient & Prescribing Data

The outcome analysis included 25 patients with H3 G34-mutant DHG; the RNA-seq analysis included 110 tumors.

No treatment regimen or prescribing data are reported. The authors caution that MGMT expression should not guide therapy without validation in larger, prospective cohorts.

Clinical Best Practices

• Document pre-analytic variables in retrospective tumor cohorts.
• Normalize samples and correct for batch effects before comparing RNA-seq expression.
• Identify and remove low-complexity libraries, which the authors report cannot be rescued through correction.
• Test whether adjustment for pre-analytic and technical variables changes marker–outcome associations.
• Confirm key findings using an independent assay.

Related Resources & Content